July 18th, 2017

Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson’s Disease: Company Will Receive Cash and Stock and Plans to Pay One Third of the Shares Received in a Dividend to Shareholders
View Release

June 21st, 2017

Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials
View Release

June 8th, 2017

Rich Pharmaceuticals Announces Institutional Review Board Submission
View Release

May 31st, 2017

Rich Pharmaceuticals Announces Clinical Site in Thailand
View Release

May 9th, 2017

Rich Pharmaceuticals’s Division CannCodex, Releases List of Conditional Use Permits Issued in California to Medicinal Cannabis Businesses
View Release

April 10th, 2017

Rich Pharmaceuticals Welcomes New Board Member
View Release

April 6th, 2017

Rich Pharmaceuticals announces Industry Veteran to Join CannCodex
View Release

March 21st, 2017

Rich Pharmaceuticals To Launch CannCodex, marking its entry into Medicinal Cannabis Industry
View Release

February 28th, 2017

Rich Pharmaceuticals Attracts New Financing Package with GHS Investments, LLC
View Release

September 27th, 2016

Rich Pharmaceuticals, Inc. Announces Quarterly Milestones
View Release

June 21st, 2016

Rich Pharmaceuticals Retains Theradex Systems To Help Advance Its Hodgkin’s Lymphoma Indication
View Release

April 4th, 2016

Rich Pharmaceuticals Retains Contract Research Organization, CMIC, to Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in Thailand
View Release

March 30th, 2016

Rich Pharmaceuticals Further Extends CRO Agreement with Theradex Systems To Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in the United States
View Release

February 16th, 2016

Rich Pharmaceuticals, Inc. Highlights Goals and Objectives for 2016
View Release

February 10th, 2016

Rich Pharmaceuticals, Inc. Announces Reverse Split
View Release

December 28th, 2015

Rich Pharmaceuticals, Inc. Receives FDA Approval for a Phase 1/2 Study in AML & MDS
View Release

November 23rd, 2015

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)
View Release

October 7th, 2015

Rich Pharmaceuticals Retains Theradex Systems To Finalize Investigational New Drug Application And Initiate Next Phases Of Clinical Trials
View Release

August 13th, 2015

Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
View Release

March 18th, 2015

Rich Pharmaceuticals, Inc. Names Chittima Sirijerachai, MD as Principal Investigator for Upcoming AML Clinical Trials
View Release

Stock Price